Actos—pioglitazone—is one of the best-selling drugs in the United States, used in the treatment of Type 2 diabetes. Actos gained FDA approval some thirteen years ago, and despite numerous reports of adverse health symptoms linked to Actos.

Actos is a drug frequently prescribed for those with Type 2 diabetes. Takeda, a Japanese pharmaceutical company, began manufacturing Actos in 1999.

Actos (pioglitazone) is a prescription drug used in the treatment of Type 2 Diabetes. Approved in 1999, the drug has been on the market for over thirteen years, and at one time was considered a safe alternative to the drug Avandia (which was targeted for contributing to adverse cardiovascular events in users).

Despite these negative reports, the sales of Actos continued to skyrocket with its manufacturer, Takeda, netting over $3 billion dollars for the sale of Actos in 2010 alone.

Actos (pioglitazone hydrochloride) is a prescription drug used in the treatment of ‘Type 2’ Diabetes and was approved for use some thirteen years ago.

Actos is a prescription drug manufactured by Takeda, a Japanese pharmaceutical corporation, over thirteen years ago and is used in the treatment of Type 2 diabetes. While there were many adverse health issues reported among users of Actos

This article continues the discussion of the Kaiser Permanente study, conducted over a period of ten years which attempted to determine the risk of bladder cancer in those taking the Type 2 diabetes drug, Actos. Incomplete or missing data were considered potential confounders, or variables which could change the results of the study.

This two-part article series will detail a ten-year study between 1997 and 2008 done to determine the relative risk of developing bladder cancer among diabetic patients who were being treated with the drug Actos in an effort to control their diabetic symptoms. After receiving adverse reports regarding the safety of Actos, the FDA requested the manufacturer of Actos, Takeda, conduct a safety study in order to determine whether Actos therapy directly increased the risk of bladder cancer.

Continuing from part one which details the particulars of the pending Actos lawsuits, part two will talk about the MDL case as well as case law which may pertain to Actos suits. The discussion at a recent attorney’s conference regarding Actos litigation discussed the highlights of the MDL Actos case.

Nearly thirteen years ago a new diabetic drug, Actos, was approved for the treatment of Type 2 diabetes. Takeda, the Japanese manufacturer of Actos collaborated with Eli Lilly to release the drug in the United States at the time. At the same time Actos was approved, a close competitor, Avandia, was also approved.

The blockbuster drug, Actos, which is prescribed to control Type 2 diabetes, has received new warning language on the label regarding a potential risk of bladder cancer for those taking the drug. Actos, also known as pioglitazone, is manufactured by Takeda Pharmaceuticals, a Japanese-based company, and is currently their best-selling drug, with sales of $3.4 billion last year alone.

Many of us would be very surprised to find that a drug can be approved by the FDA yet still have serious—and undisclosed—side effects. The drug Actos, used in the treatment of Type 2 diabetes, is one such drug. Actos works by decreasing the body’s resistance to insulin as a way of controlling blood sugar levels. Actos is currently being used by millions of people across the globe, with sales jumping from around $2.9 billion in 2006 to over $4.3 billion in 2010.

Actos, or pioglitazone, is a prescription medicine used in the treatment of Type-2 diabetes and works by sensitizing cells to the pancreas-produced hormone known as insulin. Insulin is used by the body to regulate the amount of sugar or glucose in the body therefore when cells are more sensitive to insulin, sugar in the blood naturally moves more easily into cells.

Actos, a drug used in the treatment of Type 2 Diabetes has been shown to carry a risk of bladder cancer, particularly among those who are elderly or who have taken the drug in higher doses or for extended periods of time (longer than one year). Although the drug has not yet been recalled by the FDA, it has fallen under intense scrutiny and has been pulled from the French and German markets.

The drug Actos, also known as pioglitazone, has recently come under fire due to studies showing a slight increased risk of bladder cancer in those taking high doses of the drug or those who have taken Actos for longer than two years. Manufactured by Takeda Pharmaceuticals of Japan, the drug has shown huge gains in popularity in the past few years as it quickly replaced the drug Avandia which suffered under claims of increased risk of heart attack and death.

While many people are now aware of the association between the Type 2 diabetes drug, Actos, and both bladder cancer and heart disease, there are several other quite serious side effects also associated with the drug. For instance, there is strong evidence to suggest that Actos, like its sister-drug, Avandai, may cause osteoporosis and bone fractures among those taking it, most especially in female patients.

Following safety reviews of the drug pioglitazone—a medicine used in the treatment of Type 2 diabetes—the European Medicines Agency delivered their decision that while there is a marginally increased risk of bladder cancer in those taking the drug, it remains a viable treatment option for some patients.

The FDA has joined forces with France and Germany regarding a warning about the Type 2 diabetes drug, pioglitazone, however no recall is expected at this time. Pioglitazone, also known as Actos, is manufactured by Takeda Pharmaceuticals, a Japanese drug company.

Although the FDA issued recommendations regarding labeling cautions for the drug Actos to manufacturer Takeda Pharmaceuticals in 2006, following further safety reviews of the drug they have recently issued more stringent instructions to the Japanese company. Actos, also known as pioglitazone is used in the treatment of Type 2 diabetes to help control the levels of sugar in the blood.

Links to higher heart disease rates have been associated with the use of Actos, and, in fact, Actos may cause as many heart problems as GlaxoSmithKline’s drug, Avandia. The American Heart Association reported that studies showed patients taking either diabetes drug were at least four times as likely to experience heart attacks, heart failure or even death.

Hundreds of thousands of patients who have taken the drug Actos over the past few years—believing the drug to be safe—have been very disillusioned to find that the drug can have some potentially very serious side effects. Actos is a drug which was developed for the treatment of Type 2 diabetes and works by helping the body restore its normal response to insulin, effectively lowering blood sugar.

The European Medicines Agency released a scientific study on the benefits and risks of the drug pioglitazone, also known as Actos, in January of 2007. This drug is currently used as a single treatment for Type 2 diabetes or in a dual combination form with metformin or sulphonylurea. When used alone, pioglitazone is typically used as therapy for the overweight patient whose Type 2 diabetes is not being controlled through diet and exercise and for whom the drug metformin is inappropriate.

Actos is a widely-used medication for the treatment of Type 2 diabetes. Actos works by helping to regulate blood sugar levels, making your body more insulin-sensitive. Doctors frequently recommend taking Actos in conjunction with a sensible diet and regular exercise for those who have the type of diabetes which does not necessitate taking insulin.

The health review of the Type 2 diabetic drug, pioglitazone, performed by the European Medicines Agency, confirmed the drug remains a valid treatment option for certain patients while acknowledging a minimal increase in bladder cancer risk.

After a Journal of American Medical Association publication of a meta-analysis suggested that long-term use of the diabetes drug Avandia was associated with an increased risk of myocardial infarction, the maker of Avandia, GlaxoSmithKline, declared there was little difference in the safety profile of their drug, Avandia and the “other” drug for Type 2 diabetes, Takeda Pharmaceutical’s Actos. Further studies however have not completely backed up that declaration.

The Type 2 diabetes drug Actos is one of a class of drugs known as thiazolidinediones and has recently been linked to an increased risk of bladder cancer, liver disease and cardiovascular issues. The FDA felt that the link between heart failure and Actos was serious enough to require increased warnings on the drug packaging concerning congestive heart failure.

A wave of recent studies which definitively link the prescription drug Actos—prescribed for Type 2 diabetes—to bladder cancer gives a fairly clear indication that Takeda Pharmaceuticals may soon be flooded with Actos lawsuits. August, 2011, saw the first Actos lawsuit filed by a 54-year old woman from Pennsylvania who had taken Actos for over a decade, then was diagnosed with bladder cancer.

United States Food and Drug Administration informed the public that using the drug Actos, commonly prescribed in the treatment of Type 2 diabetes, has been positively associated with an increased risk of bladder cancer. Actos is manufactured by a Japanese pharmaceutical company, Takeda Pharmaceuticals, and is typically sold either as a single-ingredient product or in combination with the drug metformin.

Recent studies have shown that patients taking the drug Actos for longer than one year may suffer significantly increased risks of developing bladder cancer. The FDA warnings are being issued on the heels of France and Germany banning the use of Actos, and New Zealand also beginning the process of removing Actos from patient use.

The drug Actos, marketed by Takeda Pharmaceutical Corporation, is used in the treatment of Type 2 diabetes. Actos largely replaced its predecessor, Avandia, after Avandia was found to have serious risks of heart attack and heart failure. At the time, it was believed that Actos offered much less risk of cardiovascular damage than Avandia. Actos is used to lessen blood glucose labels and improves how the body handles insulin.

The drug Actos, also known as pioglitazone is marketed by Takeda Pharmaceuticals and Eli Lilly for the treatment of Type 2 diabetes. The drug was approved in 1999, and although the manufacturer touts it as a miracle drug which has reduced the number of diabetes cases by as much as 70%, the side effects may far outweigh the benefits. A study done in 2003 by the Mayo Clinic definitively linked Actos to swelling in the feet, lung fluid retention, shortness of breath and congestive heart failure.